Macrogol 3350 with sulfate, ascorbate, KCl & NaCl (bowel prep)
Brand names: Moviprep, Plenvu
This combination of macrogol 3350 with sodium sulfate, ascorbic acid, sodium ascorbate, potassium chloride and sodium chloride is an oral bowel-cleansing preparation used before colonoscopy, bowel surgery or radiological imaging.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
The macrogol and sodium sulfate act as osmotic agents that draw large volumes of water into the colon to produce a watery purge, while the ascorbate component contributes additional osmotic effect, together evacuating the bowel without significant net absorption.
Prescribing in practice
- Bowel-cleansing solutions can cause clinically significant dehydration and electrolyte disturbance, so they are contraindicated in gut obstruction or perforation, ileus, toxic colitis and severe dehydration, and used with caution in frail, elderly, renally or cardiac-impaired patients.
- Adequate intake of clear fluids alongside the preparation is essential, and the ascorbic acid content makes it unsuitable for patients with glucose-6-phosphate dehydrogenase deficiency.
- Oral medicines taken around the time of the purge may be incompletely absorbed, so the timing of essential drugs should be reviewed.
Monitoring
Assess hydration, renal function and electrolytes before and, where indicated, after administration in patients at risk of fluid or electrolyte depletion.
Counselling the patient
- Follow the split-dose timing exactly and drink plenty of the recommended clear fluids to avoid dehydration.
- Expect frequent watery stools; stay near a toilet once you start.
- Report dizziness, palpitations, severe abdominal pain or persistent vomiting promptly.
Evidence & guidelines
Low-volume macrogol-ascorbate bowel preparations are widely used in UK endoscopy services as an effective alternative to standard-volume regimens, with MHRA advice emphasising hydration and electrolyte safety.
Reference: NICE CG118; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Harvey-Bradshaw Index for Crohn's Disease · Inflammatory Bowel Disease
- Mayo Score for Ulcerative Colitis Activity · Inflammatory Bowel Disease
- Rome IV Criteria for Irritable Bowel Syndrome · Functional GI
- Crohn's Disease Activity Index (CDAI) · Inflammatory Bowel Disease
- Truelove and Witts Severity Index for Ulcerative Colitis · Inflammatory Bowel Disease
- Ulcerative Colitis Endoscopic Index of Severity (UCEIS) · Inflammatory Bowel Disease
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021